### Supplemental Table 3. Change From Baseline in Selected Ophthalmologic Parameters During Double-Blind Treatment (safety population)

<table>
<thead>
<tr>
<th>Parameter, Unit</th>
<th>Cariprazine Modal Daily Dose</th>
<th>Placebo N=584</th>
<th>1.5-3 mg N=539</th>
<th>4.5-6 mg N=575</th>
<th>9-12 mg N=203</th>
<th>Overall N=1317</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>n²</td>
<td>Mean (SD)</td>
<td>n²</td>
<td>Mean (SD)</td>
<td>n²</td>
</tr>
<tr>
<td>IOP, right eye</td>
<td>Baseline</td>
<td>250</td>
<td>15.7 (2.9)</td>
<td>162</td>
<td>16.1 (2.9)</td>
<td>249</td>
</tr>
<tr>
<td></td>
<td>Change at endpoint</td>
<td>250</td>
<td>-0.5 (2.3)</td>
<td>162</td>
<td>-0.0 (2.1)</td>
<td>249</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IOP, left eye</td>
<td>Baseline</td>
<td>250</td>
<td>15.8 (2.8)</td>
<td>162</td>
<td>16.1 (2.8)</td>
<td>249</td>
</tr>
<tr>
<td></td>
<td>Change at endpoint</td>
<td>250</td>
<td>-0.4 (2.1)</td>
<td>162</td>
<td>-0.1 (2.0)</td>
<td>249</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visual acuity,</td>
<td>Baseline</td>
<td>248</td>
<td>0.084 (0.2)</td>
<td>162</td>
<td>0.094 (0.3)</td>
<td>249</td>
</tr>
<tr>
<td>right eye</td>
<td>Change at endpoint</td>
<td>248</td>
<td>-0.019 (0.2)</td>
<td>162</td>
<td>-0.008 (0.2)</td>
<td>249</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visual acuity,</td>
<td>Baseline</td>
<td>248</td>
<td>0.085 (0.2)</td>
<td>162</td>
<td>0.110 (0.3)</td>
<td>248</td>
</tr>
<tr>
<td>left eye</td>
<td>Change at endpoint</td>
<td>248</td>
<td>-0.017 (0.2)</td>
<td>162</td>
<td>-0.010 (0.2)</td>
<td>248</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nuclear opalescence, Baseline</td>
<td></td>
<td>250</td>
<td>0.76 (0.8)</td>
<td>162</td>
<td>0.70 (0.8)</td>
<td>250</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Condition</td>
<td>Baseline</td>
<td>Change at endpoint</td>
<td>Change at endpoint</td>
<td>Change at endpoint</td>
<td>Change at endpoint</td>
<td>Change at endpoint</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>----------</td>
<td>--------------------</td>
<td>--------------------</td>
<td>--------------------</td>
<td>--------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Nuclear opalescence, left eye</td>
<td>250</td>
<td>0.76 (0.8)</td>
<td>162</td>
<td>0.71 (0.8)</td>
<td>251</td>
<td>0.73 (0.8)</td>
</tr>
<tr>
<td></td>
<td>250</td>
<td>0.03 (0.4)</td>
<td>162</td>
<td>-0.03 (0.4)</td>
<td>251</td>
<td>0.03 (0.4)</td>
</tr>
<tr>
<td>Nuclear color, right eye</td>
<td>250</td>
<td>0.66 (0.7)</td>
<td>162</td>
<td>0.66 (0.8)</td>
<td>250</td>
<td>0.65 (0.7)</td>
</tr>
<tr>
<td></td>
<td>250</td>
<td>0.03 (0.3)</td>
<td>162</td>
<td>-0.04 (0.4)</td>
<td>250</td>
<td>0.01 (0.3)</td>
</tr>
<tr>
<td>Nuclear color, left eye</td>
<td>250</td>
<td>0.66 (0.7)</td>
<td>162</td>
<td>0.67 (0.8)</td>
<td>251</td>
<td>0.64 (0.7)</td>
</tr>
<tr>
<td></td>
<td>250</td>
<td>0.04 (0.3)</td>
<td>162</td>
<td>-0.03 (0.4)</td>
<td>251</td>
<td>0.04 (0.3)</td>
</tr>
<tr>
<td>Cortical cataract, right eye</td>
<td>250</td>
<td>0.24 (0.4)</td>
<td>162</td>
<td>0.24 (0.4)</td>
<td>250</td>
<td>0.27 (0.5)</td>
</tr>
<tr>
<td></td>
<td>250</td>
<td>0.03 (0.3)</td>
<td>162</td>
<td>-0.01 (0.2)</td>
<td>250</td>
<td>-0.01 (0.2)</td>
</tr>
<tr>
<td>Cortical cataract, left eye</td>
<td>250</td>
<td>0.24 (0.4)</td>
<td>162</td>
<td>0.25 (0.4)</td>
<td>251</td>
<td>0.27 (0.5)</td>
</tr>
<tr>
<td></td>
<td>250</td>
<td>0.02 (0.3)</td>
<td>162</td>
<td>-0.02 (0.2)</td>
<td>251</td>
<td>0.00 (0.2)</td>
</tr>
<tr>
<td>Posterior subcapsular</td>
<td>250</td>
<td>0.13 (0.1)</td>
<td>162</td>
<td>0.18 (0.3)</td>
<td>250</td>
<td>0.14 (0.1)</td>
</tr>
<tr>
<td>Condition</td>
<td>Baseline</td>
<td>Change at endpoint</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------</td>
<td>--------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cataract, right eye</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>250 0.15 (0.2)</td>
<td>162 0.17 (0.3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>251 0.14 (0.1)</td>
<td>74 0.13 (0.1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>487 0.15 (0.2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Posterior subcapsular cataract, left eye</td>
<td>Base</td>
<td>Change at endpoint</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>250 0.00 (0.1)</td>
<td>162 -0.01 (0.1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>250 0.00 (0.2)</td>
<td>74 0.02 (0.1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>487 0.00 (0.1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*a n=number of patients within a specific category.

Based on studies RGH-MD-05 and RGH-MD-06, which used newer ophthalmology report forms. Only patients with baseline and endpoint values were included in analyses.

IOP, intraocular pressure.